In lung cancer, PD-1 and PD-L1 inhibitors have shown promising outcomes for selected patients based on their PD-L1 status, with partial or even complete tumor regression in the case of pulmonary adenocarcinomas [12,13,14]. This evidence concerns the gene CD274 and neoplasm.